Evommune (EVMN) EBITDA Margin (2025)
Evommune (EVMN) posted quarterly EBITDA Margin of 133.28% for Q3 2025, up 73.4% quarter-over-quarter from 501.07% in Q1 2025.
Powered by 
Analysis
Evommune (EVMN) EBITDA Margin (2025) Analysis & Trends
Evommune (EVMN) has reported EBITDA Margin for 1 consecutive years, with 133.28% the latest figure, recorded in Q3 2025.
- In Q3 2025, EBITDA Margin changed N/A year-over-year to 133.28%; the TTM figure through Mar 2026 stood at 631.0% (changed N/A YoY), while the FY2025 annual figure was 623.62%, up 37656.0% from the prior year.
- EBITDA Margin rose to 133.28% in Q3 2025 per EVMN's latest filing, from 501.07% in the prior quarter.
- Across five years, EBITDA Margin topped out at 133.28% in Q3 2025 and bottomed at 501.07% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Evommune | 448.44 Mn | 247.65 Mn | - | - |